AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ARTV

Horan Christopher sold $116K of ARTV

Horan Christopher (Chief Tech Operations Officer) sold 10,366 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.12M total) on 2026-09-03.

Original reporting
SEC EDGAR · Horan Christopher
Published Sep 4, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
medium confidence
Mentioned
$ARTV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the market significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Insider retains large stake (283,084 shares) indicating continued confidence.

Relevance 4/10Novelty 3/10Timing: post-market 2026-09-04

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

Chief Tech Operations Officer sold 10,366 shares for $115,637.91 on 2026-09-03.

Expected impact

Potential slight downward pressure on ARTV stock.

Evidence & confidence

Sale may indicate reduced confidence, but amount is small relative to holdings.

Market effects

Sector

Minimal impact on biotech sector.

Regional

No significant regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ARTV.

  • Insider
    Christopher Horan

    Chief Tech Operations Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

AUG 6
$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a

SEC EDGAR 8-K6 min